title: [An evaluation study on arbekacin for MRSA-infectious diseases including pneumonia, septicemia and others].
abstract: Availability of arbekacin (ABK) was analyzed in the chemotherapy of 24 MRSA-infected patients with symptoms of pneumonia (12), sepsis (6) and others (6). Most patients had background diseases such as malignant tumors or cerebrovascular disorders. 47% (7/15) of them were immunologically abnormal. 17 of them had been previously treated with cephems, imipenem, minocycline or fosfomycin. The ABK therapy was performed with doses ranging 50-400 mg a day, divided into 1-3 times (mostly 100 mg x 2), and for 5-24 days. (18 patients were treated between 5 and 14 days). 14 patients (58%) received combined therapy with other antibiotics (mostly with beta-lactams, 12). The clinical efficacy rate of the ABK therapy was 62% (good, 13; fair, 4; ineffective, 4; unknown, 3). The bacteriological efficacies were: eradicated, 7 (44%); decreased, 4; no change, 5; unknown, 8. Side effects were found in 3 patients (oliguria, 2; eruption due to drug, 1) and one case resulted in serious renal disorder. Abnormal laboratory data were found in 7 cases. Above results have indicated that ABK is a useful antibiotic in chemotherapy of MRSA-infections.
authors.affiliation: Department of Respiratory Diseases, Kanagawa Prefectural Cardiovascular and Respiratory Disease Center.
authors.forename: S
authors.initials: S
authors.lastname: Odagiri
authors.forename: M
authors.initials: M
authors.lastname: Sumitomo
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: F
authors.initials: F
authors.lastname: Matsumoto
authors.forename: I
authors.initials: I
authors.lastname: Sakurai
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: K
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: A
authors.initials: A
authors.lastname: Ito
authors.forename: M
authors.initials: M
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology; D003982:Dibekacin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; C031986:arbekacin